A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said. The individual died on December 14 ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.

Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...

Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100% vaccine efficacy Median CDI duration was 1 versus ...

SAN FRANCISCO -- One of the front-runners in the quest for a COVID-19 vaccine is reporting hopeful news. Pfizer says its vaccine is proving to be safe during phase three trials. RELATED: Oxford, ...

Pfizer (PFE) stock is in focus as the firm with Astellas (ALPMF) post a Phase 3 trial win for Padcev cancer drug when used with Merck's (MRK) Keytruda. Read more here.

Danuglipron, a weight-loss pill, won’t continue its stages of testing after a person in a clinical trial was reportedly injured. Pfizer plans to explore other obesity treatments for testing. Pfizer is ...

New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have completed recruitment for the ...

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

Pfizer (PFE) stock in red as the company reports a patient death in a clinical trial for its hemophilia therapy Hympavzi.